July 7, 2014 Washington, DC; Mallinckrodt, a global specialty pharmaceutical company, today announced the appo intment of Mark Tyndall as Vice President, Government Affairs, Policy and Advocacy. In this role, he heads Mallinckrodt’s Washington office and has global responsibility for the company's interaction with governments, stakeholder groups and trade associations. Mr. Tyndall joins the company from Bayer Healthcare, where he served as head of global policy and public affairs of the consumer health division.
Mr. Tyndall previously practiced law in the Healthcare and Government Strategies Practice Groups for Sidley Austin LLP in Washington, DC. He also served as a professional staff member for the Committee on Agriculture, Nutrition and Forestry in the United States Senate. Mr. Tyndall earned an undergraduate degree in Economics from Christopher Newport University, a Master of Public Policy degree from The College of William and Mary, and a law degree from George Washington University.
Mallinckrodt is a global specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide and a commercial presence in approximately 65 countries. The company’s fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.